Precision Therapeutics is the First Company to Grow Cancer Cells in the Lab That React Like Tumors Inside the Body -- CEOLIVE...
April 04 2018 - 12:16PM
CEOLive.TV, a news organization that highlights leading CEOs,
companies, and industry experts for investors, today
released a video interview with Dr. Carl Schwartz, CEO
of Precision Therapeutics Inc (NASDAQ:AIPT), formerly
Skyline Medical Inc (NASDAQ:SKLN).
As Dr. Schwartz explained to CEOLive.TV’s
Mike Elliott, Precision Therapeutics has the potential to
revolutionize the treatment of cancer through personalized
medicine, because it is developing a better way to grow and test
human tumors outside the body. That makes it possible to test
cocktails of drugs against individual tumors to find the right drug
combination for fighting an individual’s unique cancer. “Our
ability to replicate tumors that react like they were still in the
body gives us a leg up in this research,” said Dr. Schwartz.
Why is this so important? Cancer is actually many
thousands of different diseases, each with different underlying DNA
mutations. That’s why drugs that are effective against one person’s
ovarian cancer may fail utterly against another’s. Until now,
“dealing with tumors can often be hit or miss,” explained Schwartz.
Not only do doctors usually not know how to precisely target drugs
to use for each individual patient’s tumor mutations,
pharmaceutical companies face a difficult challenge developing and
testing new drugs. While companies are trying to grow human tumors
in mice for testing, mice are not humans, so the tests often
lead to dead ends. And though it’s possible to grow tumor cells in
petri dishes, they rarely behave like actual cancers.
Precision Therapeutics is focused on solving this
key industry problem. Through its wholly subsidiary, TumorGenesis,
it has recently licensed technology from
CellBridge, SyntArray, and 48Hour
Discovery that make it possible to take cancer cells from a
patient’s tumor and grow them on a 3D scaffold in a way that more
precisely mimics tumor growth in the body. Once this approach is
validated, and through the partnership with Helomics, drugs
can be tested on these tumors to see what kills the cancer cells,
and that information can be sent to the patients’ doctors. Because
we expect that cancer cells grown this way will react just like
tumors in the body, “the information going back to the physician
will be much more precise,” Dr. Schwartz told CEOLive.
In addition the TumorGenesis approach will be used
in conjunction with Pharma companies for the discovery of new
cancer therapies. Through the partnership with Helomics, patient
tumors, (with appropriate consent), grown using the TumorGenesis
approach can be used as a high throughput platform to test novel
drugs. This information will be added to the Helomics
D-CHIP AI platform, which already has data on the drug response
profiles of over 149,000 tumors, to build a more comprehensive
picture of the drug response of the tumor and its DNA mutations. In
this way Pharma companies can rapidly screen thousands of potential
new drug candidates to develop new more precisely targeted
therapies.
As a result, Precision Therapeutics is poised to
become a leader in the rapidly expanding field of personalized
medicine. “It is a great field with tremendous growth potential,”
said Dr. Schwartz. “We think we will be premier in this field.”
Forward Looking Statements
This CEOLIVE.TV video interview contains
forward-looking statements within the meaning of the Securities
Litigation Reform Act. The statements reflect the Company’s current
views with respect to future events that involve risks and
uncertainties. Among others, these risks include failure to meet
schedule or performance requirements of the Company’s contracts,
the Company’s ability to raise sufficient development and working
capital, the Company’s liquidity position, the Company’s ability to
obtain new contracts, the emergence of competitors with greater
financial resources, and the impact of competitive pricing. In the
light of these uncertainties, the forward-looking events referred
to in this release might not occur as planned or at all.
Disclaimer
Neither CEOLIVE.TV or any of its principals
currently own or plan to own within 72 hours of publication any
shares of the stocks mentioned in this video. For a full disclaimer
please visit, ceolive.tv/disclaimer.
CEOLIVE content and productions are based on data
obtained from sources we believe to be reliable but are not
guaranteed as to accuracy and are not purported to be complete. As
such, the information should not be construed as advice designed to
meet the particular investment needs of any investor. Any opinions
expressed in CEOLIVE content and productions, or other investor
relations materials and presentations are subject to change.
Neither CEOLIVE nor any of its data or content providers shall be
liable for any errors or delays in the content, or for any actions
taken in reliance thereon. All data and information are provided
for informational or entertainment purposes only. CEOLIVE is not a
registered broker-dealer or a registered investment advisor.
Contact:
CEOLIVE.TV
Mike Elliott
me@ceolive.tv
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Apr 2023 to Apr 2024